Regarding clinical parameters, we found patients with mutated IKZF1 to less frequently present with de novo AML (71.1% vs. 83.7%, p = 0.038), while there was no significant difference with regard to sAML or tAML. This evidence concerns the gene IKZF1 and acute myeloid leukemia.